%D9%84%D9%8A%D8%AF%D9%8A%D8%A8%D8%A7%D8%B3%D9%81%D9%8A%D8%B1Category:LedipasvirLedipasvirLedipasvirLedipasviiriL%C3%A9dipasvirLedipasvir%E3%83%AC%E3%82%B8%E3%83%91%E3%82%B9%E3%83%93%E3%83%AB%EB%A0%88%EB%94%94%ED%8C%8C%EC%8A%A4%EB%B9%84%EB%A5%B4LedypaswirLedipasvir%D0%9B%D0%B5%D0%B4%D0%B8%D0%BF%D0%B0%D1%81%D0%B2%D0%B8%D1%80LedipasvirLedipasvir%D0%9B%D0%B5%D0%B4%D1%96%D0%BF%D0%B0%D1%81%D0%B2%D1%96%D1%80LedipasvirQ15409409%E9%9B%B7%E8%BF%AA%E5%B8%95%E9%9F%A6
about
P2176
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) InfectionEfficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV InfectionEfficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV InfectionTreatment of Egyptian Hepatitis C Genotype 4 Infected Children and Adolescents With Combined Ledipasvir/SofosbuvirChronic Hepatitis C Treatment in Egyptian Children With Gaucher Disease.Re-treatment of HCV Following DAA FailureDynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAsGS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) InfectionSerum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis CLedipasvir/Sofosbuvir for Hepatitis B Virus InfectionIFNL4 Genotype for Predicting Response to Ledipasvir/SofosbuvirSafety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-InfectionPharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological MalignancyExtrahepatic Insulin Resistance in Chronic Hepatitis CEight Weeks Sofosbovir/Ledipasvir in HCV Infected Children Aged 4 to 10 Years, a Pilot StudyHepatitis C Positive Donor Into Hepatitis C Negative RecipientsPK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders
P4844
Ledipasvir and sofosbuvir: Interferon free therapy for hepatitis C virus genotype 1 infectionVirological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort studyDrug interactions with new hepatitis C oral drugs.Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1.Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States.Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic ResponseGilead Sustained Virologic Response (SVR) RegistryOral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus InfectionOpen-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV InfectionAssociation Between Baseline Creatinine Clearance and Treatment Failure in Patients With Hepatitis C Virus Treated With Ledipasvir and SofosbuvirLedipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV InfectionProbing DNA damage induced by common antiviral agents using multiple analytical techniquesSafety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 InfectionSafety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 SubjectsSafety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCVGS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) InfectionGS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) InfectionA Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis CSafety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV InfectionSafety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C VirusLedipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV InfectionSafety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection
P921
Q61894571-36EEAD6D-4603-4DE6-A869-98C0BF338601Q61974942-F6B181C9-BED5-4D23-A4E1-D6236B115929Q61975755-35EED75A-4F1D-4249-BAB0-66EDFBC808D3Q62034650-05316464-D569-4907-A701-E0DA1F65F62AQ62039633-CF3E2AD0-8161-4714-AF01-169925CFFEC3Q62810095-0D9992E5-DF01-4ED4-B5C7-0B86E9417A71Q63229670-D303335F-FA52-4BEF-ACDD-6BA4F12075C5Q63333949-43FC3DBA-A8D1-4FC9-8861-4AA7ED36F32AQ63405440-45E36D79-98E5-408C-B03F-7BCDCE9E2363Q63571524-13BDC5DC-BC4E-49E4-AA80-51ED96178DECQ63573760-5047E82C-C208-41BB-ABF9-85D26F48F6C1Q63576929-9F303821-8121-4124-AA03-95150C02486BQ63577831-E3BFF868-8549-4233-AD27-7858E8E9BE81Q63577953-FFC3B2F9-37D4-450A-94D9-E10881D5EA2FQ63578347-003807CC-9B8F-447D-99D3-D5359D5F50F0Q63596720-38D3FB24-A580-4556-9D07-AB986F3567F8Q92272669-A2B452D4-54B7-4BD2-BAC0-1AA5069D55FB
P4844
Q35019918-F5CBE5CC-DDBB-47C3-90C2-6268A1FDE2ADQ35592257-6FA67AC9-6B48-4656-BF93-112F00607139Q38305640-D5C727E6-FAFE-4E4C-8549-A28F2C40CD6BQ38353529-8FBA796F-09A1-4CBE-9509-73C1070F1A58Q38415842-FEC621BF-6C4E-42BF-A3F9-FEEACF542EE8Q41366537-E734A361-6567-4734-A42A-C2F1BEA83A07Q41522918-AFFA6C19-9E01-46EA-B00F-8F9689AE91AEQ42173527-3FFE9E06-34E5-4EEF-A910-A9B3BC6AEBE6Q61965936-D2B2D6C0-246A-4262-B8A1-FBDC8431F040Q61965937-77F0C0DD-C69D-4E4A-B74F-14497B71F8D9Q63813013-AFC9B737-C1C9-4E27-AA60-F96D33396D55Q63817517-D44D23C0-6EAD-4168-B643-0F325B9A4ACAQ63844642-88EEC3DB-5991-4EB7-ACD4-D334257D15BEQ64285976-DECF0DD7-F889-4C6D-A8DF-B89DFBF4DC32Q64352209-7838C13B-2029-4385-BC97-658D74288D1AQ64389535-B3446A07-627B-4842-8B60-50708119EFC3Q64396619-C646A5A8-DFE5-42D7-8A00-086C974C36AAQ64637407-24B4E99C-DDE8-4815-9391-C42A798CE332Q64640431-012F5FD7-2565-4703-9A9C-E71C66D862D1Q64647992-F17E86B4-3350-4A9A-BBC1-548E7156EE30Q64648046-AA1E60C5-0DDD-41B3-AE70-AE4668934BF1Q64652349-9D2B5F85-5C8A-4006-B4A5-581D54B3F7B8Q65345918-BB5C24C2-A9F3-46F9-B9F4-7081AF4F2799Q65364666-3F03AE90-26AD-4D73-8A3C-A885AB347708Q65376092-1CECA549-0034-413F-9FA1-2C1078A44462Q66342198-5D0AC106-CA01-40D8-8FE2-0B385B9F9145Q67127074-C4BBA2F8-D938-4888-85D6-52D502871F71
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Ledipasviiri
@fi
Ledipasvir
@es
Ledipasvir
@fr
Ledipasvir
@it
Ledipasvir
@sh
Ledipasvir
@sr
Ledipasvir
@vi
ledipasvir
@en
ledipasvir
@nn
ledipasvir
@pt
type
label
Ledipasviiri
@fi
Ledipasvir
@es
Ledipasvir
@fr
Ledipasvir
@it
Ledipasvir
@sh
Ledipasvir
@sr
Ledipasvir
@vi
ledipasvir
@en
ledipasvir
@nn
ledipasvir
@pt
altLabel
GS 5885
@en
GS-5885
@en
GS5885
@en
WHO 9796
@en
prefLabel
Ledipasviiri
@fi
Ledipasvir
@es
Ledipasvir
@fr
Ledipasvir
@it
Ledipasvir
@sh
Ledipasvir
@sr
Ledipasvir
@vi
ledipasvir
@en
ledipasvir
@nn
ledipasvir
@pt
P31
P486
P592
P6366
P661
P662
P665
P683
P117
P1579
P2017
CC(C)[C@@H](C(=O)N1CC2(CC2)C[C ...... )[C@H](C(C)C)NC(=O)OC)NC(=O)OC
P2067
888.413438
P2115
N0000191095
P2175
P231
1256388-51-8
P233
CC(C)C(C(=O)N1CC2(CC2)CC1C3=NC ...... C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC